Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Study cohort began collecting data on newborns through adulthood, and may offer objective clues on asthma and COPD disease ...

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next.

A new national survey of Canadian adults reveals significant gaps in understanding of shingles risk factors and a lack of ...

The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, ...

Once people don’t have justifiable access to medicine, the disease will stay longer with those people. Some will end up dying ...

The vaccine contract manufacturing market is expanding rapidly, driven by rising global demand for immunization and a growing emphasis on preventive healthcare. Biobanks play a crucial role by ...